Literature DB >> 3972987

Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth.

L B Heifets, M D Iseman.   

Abstract

The test of susceptibility to pyrazinamide requires an acid environment (pH less than or equal to 5.5). This, however, is not favorable to the growth of Mycobacterium tuberculosis, especially in solid agar media. To obviate this difficulty, we developed a testing method with 7H12 broth medium and based on radiometric readings of the growth. The radiometric method employed in this study (BACTEC system) provides an opportunity to detect the dynamics of growth by daily recording of the growth index, which reflects the metabolic activity of the multiplying bacteria. In our technique, M. tuberculosis isolates were initially cultivated at pH 6.8. After logarithmic growth had begun, phosphoric acid solution was added to obtain pH 5.5. When pyrazinamide was added simultaneously with the acid, the growth index of susceptible cultures decreased, whereas it continued to increase in pH 5.5 control vials and in tests with pyrazinamide-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972987      PMCID: PMC271613          DOI: 10.1128/jcm.21.2.200-204.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

2.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

Authors:  K Konno; F M Feldmann; W McDermott
Journal:  Am Rev Respir Dis       Date:  1967-03

3.  [Sensitivity of tubercle bacilli to pyrazinamide determined on the basis of their sensitivity to nicotinamide and their pyrazinamidase and nictinamidase activities].

Authors:  J Tatar
Journal:  Gruzlica       Date:  1974-08

4.  A simple way of detecting pyrazinamide resistance.

Authors:  E Brander
Journal:  Tubercle       Date:  1972-06

5.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  S H Siddiqi; J P Libonati; G Middlebrook
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

6.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

7.  Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

Authors:  G Middlebrook; Z Reggiardo; W D Tigertt
Journal:  Am Rev Respir Dis       Date:  1977-06

8.  Radiometric detection of the metabolic activity of Mycobacterium tuberculosis.

Authors:  D M Cummings; D Ristroph; E E Camargo; S M Larson; H N Wagner
Journal:  J Nucl Med       Date:  1975-12       Impact factor: 10.057

9.  Rapid drug-susceptibility testing of Mycobacterium tuberculosis.

Authors:  D E Snider; R C Good; J O Kilburn; L F Laskowski; R H Lusk; J J Marr; Z Reggiardo; G Middlebrook
Journal:  Am Rev Respir Dis       Date:  1981-04

10.  Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility.

Authors:  J K McClatchy; A Y Tsang; M S Cernich
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

View more
  9 in total

1.  Modified method for testing the quality of albumin-containing enrichments used in growth media for mycobacteria.

Authors:  W R Butler; N G Warren; G P Kubica; J O Kilburn
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

2.  Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.

Authors:  David Pires; Emília Valente; Marta Filipa Simões; Nuno Carmo; Bernard Testa; Luís Constantino; Elsa Anes
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

3.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Authors:  L B Heifets; M A Flory; P J Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Genotypic determination of Mycobacterium tuberculosis antibiotic resistance using a novel mutation detection method, the branch migration inhibition M. tuberculosis antibiotic resistance test.

Authors:  Y P Liu; M A Behr; P M Small; N Kurn
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  Evaluation of a radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  J J Tarrand; A D Spicer; D H Gröschel
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pushpendra Singh; Clement Wesley; G P S Jadaun; Sunil Kumar Malonia; R Das; P Upadhyay; J Faujdar; P Sharma; P Gupta; Abhay Kumar Mishra; Kalpana Singh; D S Chauhan; V D Sharma; U D Gupta; K Venkatesan; V M Katoch
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

8.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium.

Authors:  C L Woodley; R W Smithwick
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.